financetom
Business
financetom
/
Business
/
Liberty Defense Up Near 14% On Contract Win for Multiple HEXWAVE Walkthrough Screening Systems From a U.S. State Capitol Complex
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Liberty Defense Up Near 14% On Contract Win for Multiple HEXWAVE Walkthrough Screening Systems From a U.S. State Capitol Complex
Nov 17, 2025 12:34 PM

03:04 PM EST, 11/17/2025 (MT Newswires) -- Liberty Defense Holdings ( LDDFF ) shares were up near 14% on Monday after it received a competitive bid award for three HEXWAVE walkthrough screening systems at a U.S. State Capitol complex in the Northeast.

The company said the systems will support security screening for officials, employees, and visitors across two high-traffic buildings. . The HEXWAVE was selected following a public competitive tender process, it added.

""We are excited to win this tender and provide an enhanced level of security to the Capitol Buildings. Public-sector customers are modernizing entry screening to address today's broader threat profile," said Liberty Defense ( LDDFF ) Chief Executive Bill Frain. "HEXWAVE delivers detection performance for both metallic and non-metallic threats while maintaining throughput and a positive visitor experience."

Shares of the company were last seen up $0.04 at $0.33 on the TSX Venture Exchange.

Price: 0.33, Change: +0.04, Percent Change: +13.79

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
GSK's Application for Endometrial Cancer Treatment Expansion Accepted for Review in Europe
GSK's Application for Endometrial Cancer Treatment Expansion Accepted for Review in Europe
Jun 24, 2024
08:07 AM EDT, 06/24/2024 (MT Newswires) -- GSK (GSK) said Monday its application to expand the use of Jemperli with chemotherapy for adult patients with primary advanced or recurrent endometrial cancer has been accepted by the European Medicines Agency for review. The agency's Committee for Medicinal Products for Human Use will review the medicine to make a recommendation to the...
Oncolytics Biotech CEO Matt Coffey to Take Medical Leave of Absence
Oncolytics Biotech CEO Matt Coffey to Take Medical Leave of Absence
Jun 24, 2024
08:11 AM EDT, 06/24/2024 (MT Newswires) -- Oncolytics Biotech ( ONCY ) said Monday that Chief Executive Officer Matt Coffey will take a medical leave of absence, effective immediately. Wayne Pisano, chair of Oncolytics' board of directors since 2013, will serve as interim CEO during his absence. Price: 0.9900, Change: -0.02, Percent Change: -1.98 ...
Ripple effect from CDK hack widens as more US auto dealers flag hit
Ripple effect from CDK hack widens as more US auto dealers flag hit
Jun 24, 2024
June 24 (Reuters) - More U.S. auto dealers flagged a hit from an outage of CDK's software system due to a cyber attack on Monday as the company worked to restore systems used by over 15,000 retail locations across North America. AutoNation ( AN ), a leading auto retailer in the U.S. said the outage was disruptive and had adversely...
Regulus Therapeutics Says Potential Kidney Disease Drug Well-Tolerated in Phase 1b Study
Regulus Therapeutics Says Potential Kidney Disease Drug Well-Tolerated in Phase 1b Study
Jun 24, 2024
08:15 AM EDT, 06/24/2024 (MT Newswires) -- Regulus Therapeutics ( RGLS ) said Monday that results from the third cohort of patients in its phase 1b study showed that its investigational drug RGLS8429 was well-tolerated with no safety concerns. The investigational drug is being evaluated in adults with autosomal dominant polycystic kidney disease, or ADPKD. Enrolment is ongoing for the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved